医学
前列腺癌
内科学
肿瘤科
总体生存率
放射治疗
联想(心理学)
生存分析
前列腺
癌症
存活率
疾病
梅德林
比例危险模型
无进展生存期
作者
Hye Lim Park,David Kersting,Colin P. Bergstrom,Ali Raza Khaki,Jagruti C. Shah,Guido Davidzon,Farshad Moradi,Alice C. Fan,Sumit Anil Shah,Erin E. Grady,Sandy Srinivas,Andrei H. Iagaru,Song Hong
标识
DOI:10.2967/jnumed.126.272651
摘要
This article evaluates whether early same-day posttherapy whole-body SPECT/CT assessed using visual RECIP 1.0 is associated with overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) that is positive for prostate-specific membrane antigen (PSMA) and treated with [177Lu]Lu-PSMA-617, and it assesses concordance among posttherapy SPECT/CT, PSMA PET/CT, and prostate-specific antigen (PSA). Methods: We retrospectively analyzed 158 men with mCRPC who received at least 2 cycles [177Lu]Lu-PSMA-617 between June 2022 and January 2025. Same-day posttherapy SPECT/CT was performed after each cycle. Early SPECT imaging response was assessed after cycle 2 using visual RECIP 1.0. Baseline tumor burden was classified as low or high volume using CHAARTED criteria on baseline SPECT. Early biochemical response was defined as a PSA decline of at least 50% (PSA50) before cycle 3. OS was the primary endpoint. Kaplan–Meier analysis, log-rank testing, and univariable and multivariable Cox regression were performed. Interim imaging response and concordance were evaluated for SPECT/CT and PSMA PET/CT after cycle 3. Results: Median follow-up was 23.9 mo, and median OS was 14.4 mo. Early SPECT response after cycle 2 was associated with longer OS than occurred with no response (21.5 vs. 11.3 mo, P < 0.001). High-volume baseline disease and absence of PSA50 were associated with shorter OS. The combination of imaging response, baseline tumor burden, and PSA50 improved survival stratification. Patients with high-volume disease and without imaging response were associated with the shortest OS compared with those with low-volume disease and imaging response (10.6 vs. 23.7 mo, P < 0.001). Among patients who underwent interim SPECT/CT and PSMA PET/CT (n = 97), progressive disease on either modality was associated with shorter survival. SPECT, PET, and PSA responses were concordant in 59.8% of patients. Discordant findings reflected differences in imaging timing, sensitivity, and biologic heterogeneity, including PSMA-negative disease. Conclusion: Early same-day posttherapy SPECT/CT assessed using visual RECIP 1.0 was associated with OS in patients with mCRPC who received [177Lu]Lu-PSMA-617. Integration of early SPECT response, baseline tumor burden, and PSA50 improved survival stratification. Substantial concordance among SPECT, PSMA PET, and PSA response, together with characteristic discordance patterns, supports a complementary role for SPECT/CT in treatment response assessment.
科研通智能强力驱动
Strongly Powered by AbleSci AI